MATUCCI, ANDREA
 Distribuzione geografica
Continente #
NA - Nord America 2.700
EU - Europa 2.357
AS - Asia 522
OC - Oceania 23
AF - Africa 9
Totale 5.611
Nazione #
US - Stati Uniti d'America 2.695
PL - Polonia 795
RU - Federazione Russa 792
IT - Italia 319
IE - Irlanda 164
SG - Singapore 164
SE - Svezia 141
HK - Hong Kong 117
CN - Cina 99
JO - Giordania 44
GB - Regno Unito 41
IN - India 34
FI - Finlandia 31
ID - Indonesia 31
VN - Vietnam 26
CH - Svizzera 24
AU - Australia 23
BE - Belgio 14
DE - Germania 14
FR - Francia 10
CI - Costa d'Avorio 8
CA - Canada 5
UA - Ucraina 4
NL - Olanda 3
RO - Romania 3
KR - Corea 2
PH - Filippine 2
CZ - Repubblica Ceca 1
EG - Egitto 1
ES - Italia 1
IR - Iran 1
TH - Thailandia 1
TR - Turchia 1
Totale 5.611
Città #
Warsaw 794
Santa Clara 779
Fairfield 278
Chandler 178
Dublin 164
Ashburn 157
Singapore 147
Woodbridge 107
Seattle 106
Wilmington 106
Houston 105
Cambridge 103
Ann Arbor 93
Hong Kong 80
Altamura 63
Florence 63
Lawrence 63
Moscow 51
Princeton 39
Buffalo 31
Shanghai 31
Beijing 29
Jakarta 29
Mumbai 25
Boston 24
Dong Ket 24
Melbourne 23
New York 21
Kent 20
San Diego 20
Medford 19
Bern 18
Luni 18
Helsinki 16
Milan 16
Los Angeles 15
Brussels 14
Boardman 11
London 10
Abidjan 8
Norwalk 8
Rome 8
Liverpool 7
Livorno 7
Phoenix 7
Naples 6
Redwood City 6
Andover 5
Frankfurt am Main 5
Jacksonville 5
Castelliri 4
Lappeenranta 4
Redmond 4
Toronto 4
Busto Arsizio 3
Calenzano 3
Campi Bisenzio 3
Caulonia 3
Chicago 3
Genoa 3
Hillsboro 3
Paris 3
Peschiera 3
Washington 3
Yubileyny 3
Acton 2
Bengaluru 2
Bologna 2
Canosa di Puglia 2
Craiova 2
Falls Church 2
Lambeth 2
Latina 2
Laurel 2
Leawood 2
Milzano 2
Monopoli 2
Munich 2
Nanchang 2
Nerviano 2
Nola 2
Palermo 2
Parma 2
Pune 2
Romainville 2
Salerno 2
Sant'Agata Bolognese 2
Seoul 2
Sommacampagna 2
Torre del Greco 2
Varese 2
Wuhan 2
Zurich 2
Arnsberg 1
Bari 1
Birkenhead 1
Bucharest 1
Cedar Knolls 1
Central 1
Chongqing 1
Totale 4.074
Nome #
Hapten-Specific TH17 Cells in the Peripheral Blood of β-Lactam-Induced AGEP. 270
Immunoglobulin replacement therapy for yellow nail syndrome 261
The in vitro amplification of β-lactam-specific memory t cells improves the diagnostic performance of IGE detection and lymphocyte transformation test 201
Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies 178
Concomitant Bilastine and Montelukast as Additive Therapy for Seasonal Allergic Rhinoconjunctivits and Mild-to-Moderate Asthma. The SKY Study 169
Efficacy and safety of mepolizumab (Anti-Interleukin-5) treatment in Gleich's syndrome 165
Tocilizumab in Giant Cell Arteritis: A Real-Life Retrospective Study 164
High serum β-lactams specific/total IgE ratio is associated with immediate reactions to β-lactams antibiotics 163
Biweekly hizentra® in primary immunodeficiency: A multicenter, observational cohort study (IBIS) 160
Skin testing and infliximab-specific antibodies detection as a combined strategy for preventing infusion reaction. 150
Malattia di Anderson-Fabry 146
Autoimmune hepatitis in a patient affected by neuromyelitis optica: A new association. 139
Assays and strategies for immunogenicity assessment of biological agents. 134
Assessment of the risk of polyomavirus JC reactivation in patients with immune-mediated diseases during long-term treatment with infliximab 132
Miescher's cheilitis: Surgical management and long term outcome of an extremely severe case. 130
Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency in Routine Clinical Practice: The VISPO Prospective Multicenter Study 128
The Italian Registry for Primary Immunodeficiencies (Italian Primary Immunodeficiency Network; IPINet): Twenty Years of Experience (1999–2019) 127
Corrigendum to "Rapid infusions of human normal immunoglobulin 50g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia" [Int. Immunopharmacol. 44 (2017) 38-42] 127
Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes 125
Manifestations of Antidrug Antibodies Response: Hypersensitivity and Infusion Reactions. 118
Omalizumab dampens type 2 inflammation in a group of long-term treated asthma patients and detaches IgE from FcεRI 116
Subcutaneous Immunoglobulin Twenty Percent Every Two Weeks in Pediatric Patients with Primary Immunodeficiencies: Subcohort Analysis of the IBIS Study 116
The percentage of patients achieving complete remission of urticaria increases with repeated courses of treatment 112
Drug-Specific Th2 Cells and IgE Antibodies in a Patient with Anaphylaxis to Rituximab 111
Rapid infusions of human normal immunoglobulin 50g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia. 110
High proportion of inflammatory CD62Llow eosinophils in blood and nasal polyps of severe asthma patients 104
Seasonal Allergic Rhinitis Symptoms in Relation to COVID-19 99
Low-dose mepolizumab effectiveness in patients suffering from eosinophilic granulomatosis with polyangiitis 96
Prompt Predicting of Early Clinical Deterioration of Moderate-to-Severe COVID-19 Patients: Usefulness of a Combined Score Using IL-6 in a Preliminary Study 95
Clinical outcome, incidence, and SARS-CoV-2 infection-fatality rates in Italian patients with inborn errors of immunity 91
COVID-19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey 88
Allergological in vitro and in vivo evaluation of patients with hypersensitivity reactions to infliximab. 82
Persistence of both reversible airway obstruction and higher blood eosinophils may predict lung function decline in severe asthma 80
Early experience of an infectious and tropical diseases unit during the coronavirus disease (COVID-19) pandemic, Florence, Italy, February to March 2020 78
Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice 74
Circulating T cells to infliximab are detectable mainly in treated patients developing anti-drug antibodies and hypersensitivity reactions 74
The Kinetics of Antidrug Antibodies, Drug Levels, and Clinical Outcomes in Infliximab-Exposed Patients with Immune-Mediated Disorders 73
The anti-IgE monoclonal antibody omalizumab as adjuvant treatment in desensitization to carboplatin in patients with ovarian cancer 72
Effectiveness of low-dose intravenous immunoglobulin therapy in minor primary antibody deficiencies: a two-year real-life experience 72
Blood CD62Llow inflammatory eosinophils are related to the severity of asthma and reduced by mepolizumab 66
Long-term retention rate of mepolizumab treatment in severe asthma: a 36-months real-life experience 57
Anti-RuvBL1/2 Autoantibodies Detection in a Patient with Overlap Systemic Sclerosis and Polymyositis 57
Drug-specific Treg cells are induced during desensitization procedure for rituximab and tocilizumab in patients with anaphylaxis 56
Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent 53
Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent 52
Primary antibody deficiencies represent an underestimated comorbidity in asthma patients: efficacy of immunoglobulin replacement therapy in asthma control 51
Effectiveness of tocilizumab in hospitalized moderate-to-severe COVID-19 patients: a real-life study 51
EGPA Phenotyping: Not Only ANCA, but Also Eosinophils 48
Efficacy and safety of dupilumab in the treatment of CRSwNP in the real-life setting: a review of the literature 41
Case Report: A child with NFKB1 haploinsufficiency explaining the linkage between immunodeficiency and short stature 41
Baseline Eosinophil Count as a Potential Clinical Biomarker for Clinical Complexity in EGPA: A Real-Life Experience 41
Management of patients with chronic rhinosinusitis with nasal polyps (CRSwNP): Results from a survey among allergists and clinical immunologists of the North-west and Center Italy Inter-Regional Sections of SIAAIC and otorhinolaryngologists of National IAR 39
Managing Patients with Hypereosinophilic Syndrome: A Statement from the Italian Society of Allergy, Asthma, and Clinical Immunology (SIAAIC) 32
Mechanisms of Action of Ig Preparations: Immunomodulatory and Anti-Inflammatory Effects 25
Asthma remission one, none and one-hundred thousand: the relevance of the patient’s view 22
null 12
Effectiveness and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps and associated comorbidities: a multicentric prospective study in real life 5
Totale 5.679
Categoria #
all - tutte 17.973
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.973


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020417 0 0 0 0 0 0 84 100 84 63 75 11
2020/2021637 52 60 6 87 41 69 42 38 74 91 34 43
2021/2022301 5 11 18 11 11 29 18 34 16 24 47 77
2022/2023862 65 186 49 43 51 140 110 48 94 15 32 29
2023/2024519 11 29 61 30 50 56 36 99 14 43 58 32
2024/20252.077 96 282 171 484 713 331 0 0 0 0 0 0
Totale 5.679